155 related articles for article (PubMed ID: 37315225)
1. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Moreno C; Solman IG; Tam CS; Grigg A; Scarfò L; Kipps TJ; Srinivasan S; Mali RS; Zhou C; Dean JP; Szafer-Glusman E; Choi M
Blood Adv; 2023 Sep; 7(18):5294-5303. PubMed ID: 37315225
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract][Full Text] [Related]
4. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract][Full Text] [Related]
6. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
[TBL] [Abstract][Full Text] [Related]
7. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin MD; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
NEJM Evid; 2022 Jul; 1(7):EVIDoa2200006. PubMed ID: 38319255
[TBL] [Abstract][Full Text] [Related]
8. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract][Full Text] [Related]
9. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
11. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Barr PM; Tedeschi A; Wierda WG; Allan JN; Ghia P; Vallisa D; Jacobs R; O'Brien S; Grigg AP; Walker P; Zhou C; Ninomoto J; Krigsfeld G; Tam CS
Clin Cancer Res; 2022 Oct; 28(20):4385-4391. PubMed ID: 35939599
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Scarfò L; Heltai S; Albi E; Scarano E; Schiattone L; Farina L; Moia R; Deodato M; Ferrario A; Motta M; Reda G; Sancetta R; Coscia M; Rivela P; Laurenti L; Varettoni M; Perotta E; Capasso A; Ranghetti P; Colia M; Ghia P
Blood; 2022 Dec; 140(22):2348-2357. PubMed ID: 35921541
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
14. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B; Niemann CU; Kater AP; Fürstenau M; von Tresckow J; Zhang C; Robrecht S; Gregor M; Juliusson G; Thornton P; Staber PB; Tadmor T; Lindström V; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Nösslinger T; Janssens A; Christiansen I; Baumann M; Frederiksen H; van der Klift M; Jäger U; Leys MBL; Hoogendoorn M; Lotfi K; Hebart H; Gaska T; Koene H; Enggaard L; Goede J; Regelink JC; Widmer A; Simon F; De Silva N; Fink AM; Bahlo J; Fischer K; Wendtner CM; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Levin MD; van Oers M; Geisler C; Stilgenbauer S; Hallek M;
N Engl J Med; 2023 May; 388(19):1739-1754. PubMed ID: 37163621
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Huber H; Edenhofer S; von Tresckow J; Robrecht S; Zhang C; Tausch E; Schneider C; Bloehdorn J; Fürstenau M; Dreger P; Ritgen M; Illmer T; Illert AL; Dürig J; Böttcher S; Niemann CU; Kneba M; Fink AM; Fischer K; Döhner H; Hallek M; Eichhorst B; Stilgenbauer S
Blood; 2022 Mar; 139(9):1318-1329. PubMed ID: 35108374
[TBL] [Abstract][Full Text] [Related]
17. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
Levin MD; Kater AP; Mattsson M; Kersting S; Ranti J; Thi Tuyet Tran H; Nasserinejad K; Niemann CU
BMJ Open; 2020 Oct; 10(10):e039168. PubMed ID: 33060089
[TBL] [Abstract][Full Text] [Related]
18. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
Solman IG; Blum LK; Burger JA; Kipps TJ; Dean JP; James DF; Mongan A
Leuk Res; 2021 Mar; 102():106520. PubMed ID: 33611131
[TBL] [Abstract][Full Text] [Related]
19. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
Front Oncol; 2022; 12():833714. PubMed ID: 35273915
[TBL] [Abstract][Full Text] [Related]
20. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.
Lew TE; Anderson MA; Lin VS; Handunnetti SM; Came NA; Blombery P; Westerman DA; Wall M; Tam CS; Roberts AW; Seymour JF
Blood Adv; 2020 Jan; 4(1):165-173. PubMed ID: 31935286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
